Botanix Featured in AFR

/in , , /by

Health Editor for The Australian Financial Review, Michael Smith, has featured Botanix Pharmaceuticals in an article titled The five pharma stocks exciting investors.

Smith speaks to leading fund managers about their experiences and professional insights when navigating the biotechnology sector – which they say is back in favour for those willing to sort the ‘winners from the losers’ and ride the wave of success stories like CSL.

Here is an excerpt, quoting Rory Hunter, a portfolio manager for SG Hiscock’s Medical Technology Fund:

‘“It requires a diversified approach to the sector. Once the IP is validated, you are moving into commercialisation and past regulatory approvals.”

‘He likes Botanix for this reason. Its treatment for hyperhidrosis, or severe underarm sweating, affects a large part of the population, and its Japanese partner has already commercialised its treatment. “They will accelerate revenues and profitability. While their IP isn’t quite as exciting, the market they are addressing is significant,” he says.’

Click here to read the full article.

Video Available | Commercial Day Webinar

/in , , , , /by

Video is now available of the Company’s Commercial Day Webinar recorded on 17 September. In the presentation, the Botanix commercial team and their guests provide market insights and a comprehensive update on the launch plans for Sofdra™.

17 September Commercial Day Webinar – Registration Open

/in , , , /by

Join the Botanix commercial team and guests for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST for a comprehensive update on commercial launch plans and market insights for Sofdra™.

Pre-register: Click here

Appendix 4E Released and Commercial Day Webinar Announced

/in , , , /by

To view Appendix 4E, click here. Mark your calendar for the Company’s Commercial Day Webinar on
Tuesday 17 September 10:30am AEST / 8:30am AWST which will provide a comprehensive update on
commercial launch plans and market insights for Sofdra™. Registration to follow.

“Potentially Disruptive” | E&P Analysis

/in , , /by

Per E&P analyst David Nayagam, Sofdra is poised to provide a new treatment option for primary axillary hyperhidrosis, with “a novel and potentially disruptive model for marketing, reimbursement and distribution.” E&P affirms Speculative Buy and $0.55 Price Targe

View Report.

Euroz Hartleys Upgrades BOT to Buy

/in , /by

Euroz Hartleys’ Seth Lizee asserts that “the market opportunity for Sofdra is significant.” Hyperhidrosis is the third largest dermatology condition in the USA with approx. ~10m patients with axillary hyperhidrosis.” Upgraded to Buy and $0.47 Price Target.

View Report.

Botanix secures commitments for $70 million

/in , , , /by

Botanix has received firm commitments for $70 million capital raising via an institutional placement. Funds will be applied towards the launch of Sofdra™ (sofpironium) gel, 12.45%, as well as working capital and costs of the placement.

View ASX release.

Final Sofdra™ Labelling Discussions with FDA

/in , , , /by

Botanix has submitted the last label materials to the US Food & Drug Administration (FDA) for Sofdra™ a pending prescription treatment for excessive underarm sweating. Label discussions are the final step for Botanix before the anticipated FDA approval of Sofdra and have involved product carton design and wording of information that is provided to patients and physicians about the product.

Click here to view ASX release.

“Compelling Opportunity” | E&P Research Report

/in , , /by

In new research on Botanix, leading biotech analyst David Nayagam from E&P highlights the “compelling opportunity” that the Company presents and initiates coverage with a speculative buy and $0.55 price target. This increased interest in Botanix comes at a critical time, as we await the commencement of labelling discussions with the FDA – the final regulatory hurdle for Sofdra™ before expected approval in late June 2024.

View E&P Report.